Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once‐daily intravenous busulfan dosing nomogram
Open Access
- 28 March 2017
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 92 (7) , 607-613
Abstract
Busulfan, a bifunctional alkylating agent, has been used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT). The aim of this study was to derive a novel once‐daily intravenous (IV) busulfan dosing nomogram for pediatric patients undergoing HSCT using a population pharmacokinetic (PK) model. A population PK analysis was performed using 2183 busulfan concentrations in 137 pediatric patients (age: 0.6‐22.2 years), who received IV busulfan once‐daily for 4 days before undergoing HSCT. Based on the final population PK model, an optimal once‐daily IV busulfan dosing nomogram was derived. The percentage of simulated patients achieving the daily target area under the concentration‐time curve (AUC) by the new nomogram was compared with that by other busulfan dosing regimens including the FDA regimen, the EMA regimen, and the empirical once‐daily regimen without therapeutic drug monitoring (TDM). A one‐compartment open linear PK model incorporating patient's body surface area, age, dosing day, and aspartate aminotransferase as a significant covariate adequately described the concentration–time profiles of busulfan. An optimal dosing nomogram based on the PK model performed significantly better than the other dosing regimens, resulting in >60% of patients achieving the target AUC while the percentage of patients exceeding the toxic AUC level was kept <25% during the entire treatment period. A novel once‐daily busulfan dosing nomogram for pediatric patients undergoing HSCT is useful for clinicians, particularly in a setting where TDM service is not readily available or to optimize the dose on day 1.Keywords
Funding Information
- Ministry of Food and Drug Safety (16183MFDS541)
This publication has 27 references indexed in Scilit:
- Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation PatientsClinical Pharmacokinetics, 2012
- Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older ChildrenTherapeutic Drug Monitoring, 2012
- A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean PatientsThe Korean Journal of Physiology & Pharmacology, 2012
- Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in ChildrenClinical Cancer Research, 2011
- Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoringCancer Chemotherapy and Pharmacology, 2007
- Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid TumorsClinical Pharmacology & Therapeutics, 2007
- Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantationTransplantation and Cellular Therapy, 2004
- The effects of oxidative stress on the liver sieveJournal of Hepatology, 2004
- Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipientsBone Marrow Transplantation, 2001
- Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantationBone Marrow Transplantation, 2001